Noxafil Related Published Studies
Well-designed clinical trials related to Noxafil (Posaconazole)
Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. [2009.08.01]
Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. [2009.07]
Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. [2009.03]
Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. [2009.02]
Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. [2009.02]
Posaconazole: an extended-spectrum triazole antifungal agent. [2007.09]
Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. [2007.03]
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. [2007.01.25]
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. [2007.01.25]
Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. [2006.05]
A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. [2006.04.15]
Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection. [2006.02]
Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. [2005]
Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. [2004.04]
Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. [2004.03]
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. [2004.02]
Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. [2003.09]
Well-designed clinical trials possibly related to Noxafil (Posaconazole)
Aspergillosis in hematopoietic stem cell transplant recipients: risk factors, prophylaxis, and treatment. [2009.05]
A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). [2007.11]
The debate: The trials have told us very little. [2006.09]
Other research related to Noxafil (Posaconazole)
Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. [2009.11]
Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. [2009.10.05]
Current experience in treating invasive zygomycosis with posaconazole. [2009.10]
Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. [2009.08]
Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. [2009.06]
Successful treatment of Cryptococcal meningitis with a combination of liposomal amphotericin B, flucytosine and posaconazole: two case reports. [2009.05]
Posaconazole-increased vincristine neurotoxicity in a child: a case report. [2009.04]
Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole. [2009.04]
Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. [2009.03]
Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. [2009.03]
Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. [2009.02.01]
Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States. [2009.01.09]
The Pharmacokinetics and Absorption of Posaconazole Oral Suspension Under Various Gastric Conditions in Healthy Volunteers. [2008.12.15]
Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. [2008.12.01]
Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. [2008.12]
Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. [2008.12]
Clinical experience with posaconazole in patients with invasive mucormycosis: a case series. [2008.12]
Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. [2008.10]
Posaconazole: an oral triazole with an extended spectrum of activity. [2008.10]
Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. [2008.10]
Infection of the subcutis of the nose in a cat caused by Mucor species: successful treatment using posaconazole. [2008.10]
Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. [2008.10]
Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. [2008.09.27]
Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis. [2008.09]
Economic evaluation of posaconazole versus standard azole prophylaxis in high risk neutropenic patients in the Netherlands. [2008.08.27]
Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis. [2008.08]
Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. [2008.07]
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. [2008.06]
Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. [2008.03]
Mucormycosis peritonitis: more than 2 years of disease-free follow-up after posaconazole salvage therapy after failure of liposomal amphotericin B. [2008.02]
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. [2008.02]
Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/posaconazole therapy. [2008.02]
Posaconazole : a review of its use in the prophylaxis of invasive fungal infections. [2008]
Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. [2007.12.15]
Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease. [2007.12]
A review of the new antifungals: posaconazole, micafungin, and anidulafungin. [2007.12]
Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia. [2007.11]
Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats. [2007.11]
Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. [2007.09.01]
Recalcitrant Beauveria bassiana keratitis: confocal microscopy findings and treatment with posaconazole (Noxafil). [2007.09]
Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae. [2007.09]
Posaconazole therapy for chronic refractory coccidioidomycosis. [2007.09]
Posaconazole: a new broad-spectrum antifungal agent. [2007.06]
Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. [2007.06]
Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. [2007.06]
Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. [2007.06]
Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin. [2007.06]
Posaconazole for the management of mucosal candidiasis. [2007.06]
Posaconazole: a next-generation triazole antifungal. [2007.06]
Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. [2007.06]
Rhizopus microsporus var. rhizopodiformis sinus-orbital zygomycosis in an immunosuppressed patient: successful treatment with posaconazole after a complicated clinical course. [2007.05]
Posaconazole treatment for Apophysomyces elegans rhino-orbital zygomycosis following trauma for a male with well-controlled diabetes. [2007.05]
Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model. [2007.05]
Posaconazole (Noxafil): a new triazole antifungal agent. [2007.04]
Salvage treatment of histoplasmosis with posaconazole. [2007.04]
The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. [2007.04]
Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. [2007.03]
Successful treatment and limb salvage of mucor necrotizing fasciitis after kidney transplantation with posaconazole. [2007.03]
Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. [2007.03]
Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. [2007.02.15]
Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). [2007.02]
Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. [2007.02]
[The latest data on posaconazole] [2007.02]
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. [2007.01.01]
Quality control limits for posaconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue. [2007.01]
Posaconazole prophylaxis in experimental systemic zygomycosis. [2007.01]
Successful treatment of pulmonary zygomycosis with posaconazole in a recipient of a haploidentical donor stem cell transplant. [2006.12]
Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis. [2006.09]
Periorbital zygomycosis (mucormycosis) treated with posaconazole. [2006.07]
Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. [2006.07]
Treatment of cavitary pulmonary zygomycosis with surgical resection and posaconazole. [2006.07]
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. [2006.06.15]
Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. [2006.06]
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. [2006.05.15]
Control of a Candida glabrata prosthetic endovascular infection with posaconazole. [2006.05]
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. [2006.04.01]
Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. [2006.02.09]
Posaconazole as salvage therapy for zygomycosis. [2006.01]
Posaconazole for treatment of refractory invasive fungal disease. [2006]
Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. [2006]
HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. [2006]
|
